Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ITOC 2022 | Addressing the unmet needs of immunotherapy in bladder cancer

Chong Xian Pan • 29 Sep 2022
ITOC 2022 MAP 2022
Bladder Cancer Genitourinary Cancer

Chong Xian Pan, MD, PhD, Harvard Medical School, Boston, MA, discusses improving the efficacy of immunotherapy in bladder cancer. This interview took place at the Immunotherapy of Cancer (ITOC) Conference 2022 in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Chong Xian Pan

0:28
Immunotherapy + chemotherapy for bladder cancer
Chong Xian Pan • 27 Sep 2022
1:50
Potentiating immunotherapy for bladder cancer via porphyrin-based PLZ4-nanoparticles
Chong Xian Pan • 27 Sep 2022
1:36
The synergistic antitumor activity of pan-PI3K inhibition and ICI's in bladder cancer
Chong Xian Pan • 29 Sep 2022

Related Videos

0:57
Real-world outcomes of 177Lu-PSMA-617 in mCRPC
Hannah McManus • 8 Apr 2024
0:38
Emerging combinatory immunotherapies show promise for mCRPC
Hannah McManus • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals